Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation

Table 1 Patient, tumor characteristics and outcome of Bevacizumab

Patient n°	Sex	Age	Location	Initial Diagnosis		Before Treatment	Other concurrent Therapies	RANO Response at 1° follow-up	PFS
				Histology	KPS	KPS
1	F	65	R P	GBM	70	70	FTM	Partial	No progress
2	M	34	L T	AOA	80	90	-	Stable	1.3
3	M	67	R F T	GBM	90	70	FTM	Stable	4.5
4	M	27	R T P	AOD	100	80	FTM	Stable	5.0
5	M	49	L F	AOD	100	70	TMZ	Stable	2.1
6	M	41	L F	AOA	100	70	TMZ	Stable	3.1
7	M	62	L T	GBM	100	80	FTM	Stable	4.0
8	F	42	L T	AA	70	70	FTM	Stable	3.0
9	F	41	R T	GBM	80	70	TMZ	Stable	No progress
10	M	50	L T P	GBM	80	80	TMZ + FTM	Progression	2.2
11	M	60	L F P	GBM	90	90	FTM	Progression	1.6
12	M	43	CC	GBM	100	80	-	Partial	2.9
13	F	48	R T P	GBM	70	80	-	Progression	2.0
14	F	43	L T P	GBM	80	80	FTM	Partial	No progress
15	F	42	L T	AOD	100	80	-	Partial	No progress
16	M	48	L P	AOD	100	80	-	Partial	4.0

Abbreviations: Sex: M, male; F, female. Location: R, right; L, left; P, parietal; T, temporal; F, frontal; CC, corpus callosum. Histology: GBM, glioblastoma multiforme; AOA, anaplastic oligoastrocytoma; AOD, anapalstic oligodendroglioma; AA, anaplastic astrocytoma; KPS, Karnofsky performance status at initial diagnosis and before treatment with bevacizumab. FTM, fotemustine; TMZ, temozolamide. PFS, progression free survival counted from the onset of treatment with bevacizumab to radiological and/or neurological progression as months.

ISSN: 1756-9966